Aldeyra Therapeutics has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Aldeyra Therapeutics Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Aldeyra Therapeutics did not have earnings to cover the interest expense.
As of today, Aldeyra Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison
For the Biotechnology subindustry, Aldeyra Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics Financial Strength Distribution
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's Financial Strength falls into.
Aldeyra Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Aldeyra Therapeutics's Interest Expense for the
months ended in Dec. 2023 was $-0.51 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-6.10 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.27 Mil.
Aldeyra Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is
| Aldeyra Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Aldeyra Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Aldeyra Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description
Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Executives
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Todd C Brady |
director, officer: President and CEO |
C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075 |
| Martin Joseph Joyce |
director |
1050 HINGHAM STREET, ROCKLAND MA 02370 |
| Bruce Greenberg |
officer: See Remarks |
C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
| Stephen Machatha |
officer: Chief Development Officer |
131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Perceptive Advisors Llc |
10 percent owner |
51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Richard Douglas |
director |
ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
| Nancy Miller-rich |
director |
C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001 |
| Ben Bronstein |
director |
15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
| David J Clark |
officer: Chief Medical Officer |
131 HARTWELL AVE, LEXINGTON MA 02421 |
| David Mcmullin |
officer: SVP Corp. Dev. & Strategy |
C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
| Joshua Reed |
officer: Chief Financial Officer |
C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
| Jesse I Treu |
director, 10 percent owner |
|
| Stephen J Tulipano |
officer: Chief Financial Officer |
C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALDX has been successfully added to your